Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

835
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
835
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

120
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
120
Kinetics of Drug Elimination01:17

Kinetics of Drug Elimination

3.5K
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
3.5K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Akter et al. Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations. <i>Curr. Issues Mol. Biol.</i> 2025, <i>47</i>, 716.

Current issues in molecular biology·2026
Same author

Eriodictyol in Cancer Therapy: Reviewing Mechanistic Insights and Translational Opportunities.

International journal of molecular sciences·2026
Same author

Non-invasive host transcriptome and HPV oncogene expression map the molecular landscape of HPV-driven cervical lesions.

PloS one·2026
Same author

Synovium targeted colchicine therapy using pH responsive nanoparticles.

Journal of biomaterials science. Polymer edition·2025
Same author

Design, Synthesis, and Evaluation of β‑Lactamase Inhibitors as Potential Therapeutics for Antimicrobial Resistance.

ACS omega·2025
Same author

Nanosecond Pulsed Electric Fields (nsPEFs) for Precision Intracellular Oncotherapy: Recent Advances and Emerging Directions.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Aug 12, 2025

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

277

Roxadustat and its failure: A comparative dynamic study.

Kainat Gul1, Naila Zaman1, Syed Sikander Azam1

  • 1Computational Biology Lab, National Centre for Bioinformatics (NCB), Quaid-i-Azam University, Islamabad, Pakistan.

Journal of Molecular Graphics & Modelling
|January 28, 2023
PubMed
Summary

Roxadustat

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Roxadustat, a hypoxia-inducible factor prolyl hydroxylase domain 2 (HIF-PHD2) inhibitor, faced FDA rejection in Phase 3 trials.
  • Chronic kidney disease (CKD) management requires novel therapeutic strategies.
  • Understanding HIF-PHD2 inhibitor dynamics is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the molecular interactions between Roxadustat and HIF-PHD2.
  • To identify alternative FDA-approved drugs for treating renal anemia in CKD patients.
  • To explore the role of chemical scaffolds and metal ions in drug efficacy.

Main Methods:

  • Computational analysis of Roxadustat-PHD2 binding dynamics.
  • Screening of FDA-approved drugs, including Pemetrexed and Valrubicin, for potential HIF-PHD2 inhibitory activity.
Keywords:
3D-QSAR PharmacophoreMMGB/PBSAMolecular dockingMolecular dynamics simulationRoxadustat

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Experiment Videos

Last Updated: Aug 12, 2025

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

277
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
  • Comparative structural analysis of Roxadustat, Pemetrexed, Valrubicin, and control ligands (KU1, 4JR).

    • Main Results:

    • Synthetic pyrimidine-based antifolates are critical for PHD2 inhibition and erythropoietin (EPO) gene expression.
    • Metal ions (Fe+2, Mn+2) stabilize drug structures.
    • Pemetrexed and Valrubicin exhibit potential for treating CKD-related renal anemia, unlike Roxadustat.

    Conclusions:

    • Roxadustat's failure in clinical trials necessitates exploring alternative therapeutic agents.
    • Pemetrexed and Valrubicin, repurposed from cancer treatment, show promise for renal anemia in CKD.
    • Further in vitro studies are required to validate Pemetrexed and Valrubicin for renal anemia treatment.